Aerocrine Enters Distribution Agreement in Japan

Aerocrine (Solna, Sweden) has announced that the company has entered into a distribution agreement with Chest M.I. (Tokyo, Japan) to market and sell the Niox Mino asthma monitor in Japan.

The Niox Mino Airway Inflammation Monitor is a handheld device that in two minutes gauges the inflammation in the airways by measuring nitric oxide (NO) levels at exhalation. The device offers easy fingertip navigation, a touch-screen for quick and easy navigation and display of results, and a built-in flow control that keeps exhalation at 50 ml/sec regardless of patient skill. Filtering of inhaled air eliminates contamination from elevated ambient NO levels. Test cards permit individual patient data storage over time, which allows use of the device in the home environment, with 1500 measurements available.

"Chest is an ideal partner for marketing and sales of our product in Japan,” said Paul de Potocki, CEO of Aerocrine. "The company has established relations and years of experience from selling medical devices to our prime target groups. Chest has also shown an impressive knowledge and enthusiasm for our product and method of inflammatory control.”

Eight million people suffer from asthma in Japan, which causes around 3000 deaths yearly. Treatment of asthma focuses primarily on keeping the inflammation under control, which leads to fewer symptoms and less acute asthma exacerbations.


Related Links:
Aerocrine
Chest M.I.